Papers

Research literature with structured metadata.

Trials

Registered studies by status, phase, and compound.

Topics

Indications and themes psychedelics are researched for.

Compounds

Evidence across molecules with rich data.

Countries

Regulation, access, and research activity by region.

Stakeholders

Organizations shaping the space across research, policy, and funding.

People

Investigators, clinicians, and authors with mapped output.

Courses

Training programs and certifications across modalities.

Events

Conferences, workshops, and convenings by date and focus.

Results

Compare outcome data across trials and publications.

Research Snapshot

One-page overview of trials, participants, papers, and research networks.

Clinical Guidelines

Trial-anchored manuals and protocol guidance with competency mapping.

Research recaps

Monthly evidence summaries with key takeaways.

Map of research

Landscape view of trials, compounds, and outcomes.

Newsletter

Weekly or daily updates on trials, publications, analysis, and more.

Research Groups

Worldwide map of psychedelic research centres by region.

Road to Access

Science, regulation, and economics on the path to patient access.

Research Network

Interactive co-authorship map of psychedelic researchers.

Top papers

Find needles in the haystack of psychedelic research per topic.

AskBeta
Pricing

The intelligence layer for psychedelic research.

Company

  • About
  • Contact
  • Newsletter

Product

  • Feedback
  • Roadmap
  • Changelog
  • API
  • Partners
  • Clinical Guidelines

Legal

  • Privacy
  • Terms

© 2026 Blossom. All rights reserved.

Home/Research/Psilocybin/Implementation & Service Delivery

Psilocybin for Implementation & Service Delivery

10 papers and 10 clinical trials exploring psilocybin as a treatment for implementation & service delivery.

CompoundClassic Psychedelic

Psilocybin

Psilocybin is a naturally occurring tryptamine psychedelic that acts as a prodrug to psilocin, a potent 5-HT2A receptor agonist. It is the furthest advanced psychedelic in clinical development, with two positive Phase III trials in treatment-resistant depression and expanding regulated access in Australia, Germany, and US states.

Full Psilocybin profile
IndicationApproximately 264 million people worldwide suffer from depression, while substance use disorders affect around 35 million globally.

Implementation & Service Delivery

This report explores the implementation and service delivery of psychedelic therapies, focusing on compounds such as psilocybin, MDMA, and LSD in various therapeutic contexts. Recent legislative efforts and clinical trials indicate a growing acknowledgement of the therapeutic potential of psychedelics, particularly in addressing mental health conditions and substance use disorders.

Full Implementation & Service Delivery profile

Academic Research

10 papers
Open Accessmeta

Psychedelics in NHS services: exploring a model for real-world implementation of psilocybin

This commentary (2026) discusses how psilocybin could be delivered in publicly funded health services such as the NHS, focusing on the role of psychological support alongside the drug. It outlines a possible service model and emphasises that implementation should be grounded in strong evidence and equitable access.

Published
March 30, 2026
Journal
BJPsych Open
Authors
Smith, K. A., Harcourt, E., Cipriani, A.
Open Accessmeta

Developing an Ethics and Policy Framework for Psychedelic Clinical Care: A Consensus Statement

A multidisciplinary group produced a consensus ethics and policy framework for integrating government‑approved psychedelic medicines into clinical care, articulating 20 consensus points across five core ethical domains. The statement assigns responsible actors for implementation and identifies areas for further research and policy deliberation to promote equitable, safe adoption in mainstream medicine.

Published
June 4, 2024
Journal
JAMA Network Open
Authors
McGuire, A. L., Cohen, I. G., Sisti, D., Baggott, M., Celidwen, Y., Devenot, N., Gracias, S., Grob, C. S., Harvey, I., Kious, B., Marks, M., Mithoefer, M. C., Nielson, E. M., Öngür, D., Pallas, A., Peterson, A., Schenberg, E. E., Summergrad, P., Waters, B., Williams, M. T., Yaden, D. B.
Open Accessindividual

Strong Bipartisan Support for Controlled Psilocybin Use as Treatment or Enhancement in a Representative Sample of US Americans: Need for Caution in Public Policy Persists

This national survey (n=795) in the USA assesses public attitudes towards psilocybin use in licensed settings for psychiatric treatment and well-being enhancement. Participants from across the political spectrum overwhelmingly viewed the individual's decision as morally positive in both contexts, suggesting strong bipartisan support for supervised psilocybin use.

Published
February 5, 2024
Journal
AJOB Neuroscience
Authors
Sandbrink, J. D., Johnson, K., Gill, M., Yaden, D. B., Savulescu, J., Hannikainen, I. R., Earp, B. D.
Open Accessindividual

Group psychedelic therapy: empirical estimates of cost-savings and improved access

Analysing 2023 data from MDMA-assisted PTSD and psilocybin-assisted MDD trials, the authors show that group therapy markedly reduces clinician time and costs while expanding potential patient access. Group protocols cut clinician costs by 50.9% for MDMA‑PTSD (≈$3,467 per patient) and 34.7% for psilocybin‑MDD (≈$981), potentially freeing 6,711 and 1,159 FTE clinicians respectively and saving up to $10.3 billion and $2.0 billion in the US over 10 years (3% annual discount).

Published
December 6, 2023
Journal
Frontiers in Psychiatry
Authors
Marseille, E., Stauffer, C., Agrawal, M., Thambi, P., Roddy, K., Mithoefer, M. C., Bertozzi, S. M., Kahn, J. G.
Open Accessindividual

Slouching towards engagement: interactions between people using psychedelics naturalistically and their healthcare providers

In an online survey of 1,221 people using psychedelics naturalistically, disclosure to clinicians was low (22% to primary care vs 58% to psychiatric providers), 81% wanted therapist support but only 15% received it, and 23% reported same-day use with potentially interacting psychiatric medications. These findings indicate a substantial disconnect between psychedelic use and clinical care with attendant safety risks, underscoring the need for improved clinician education and policy reforms oriented to harms and benefits.

Published
August 4, 2023
Journal
Frontiers in Psychiatry
Authors
Boehnke, K. F., Cox, K., Weston, C., Herberholz, M., Glynos, N., Kolbman, N., Fields, C. W., Barron, J., Kruger, D. J.
Paywallindividual

The Canadian Psychedelic Survey: Characteristics, Patterns of Use, and Access in a Large Sample of People Who Use Psychedelic Drugs

This survey (n=2045) of Canadian psychedelic users finds psilocybin, MDMA and LSD are the most commonly used. It also reports positive (82%) life changes and challenging experiences (52%). Motivations for use include fun, self-exploration, general mental well-being, and personal growth.

Published
June 1, 2023
Journal
Psychedelic Medicine
Authors
Lake, S., Lucas, P.

Clinical Trials

10 trials
Not yet recruitingPhase II

FIFO-PAT-20: A sequential multiple assignment randomised controlled trial comparing the efficacy and safety of treatment as usual against a Fly-In-Fly-Out (FIFO) model of Psilocybin-Assisted Therapy (PAT) for Major Depressive Disorder (MDD), alongside randomised adjunctive support (virtual-reality vs journalling)

This open-label, randomised controlled Phase II trial (n=30) will test a six-week Fly-In-Fly-Out Psilocybin-Assisted Therapy (FIFO-PAT) programme for major depressive disorder (MDD), using a single 25 mg oral dose of psilocybin alongside psychotherapy and either a virtual-reality (VR) integration tool or journaling.

Started
August 4, 2025
Type
interventional
Blinding
none
Randomized
Yes
Registry ID
ACTRN12625000799459
RecruitingPhase I/II

Psilocybin-Assisted Therapy for Physician Well-Being and Burnout

Open-label single-group study (n=10) assessing feasibility, safety, and preliminary efficacy of a single 25 mg oral psilocybin dose with preparatory and integration therapy for UCSD physicians with burnout.

Started
April 1, 2025
Type
interventional
Blinding
none
Randomized
No
Registry ID
NCT06814522
RecruitingPhase I

Digital Intervention for Psychedelic Preparation (DIPP): Comparing Meditation and Music-Based Programs (DIPP-RCFT)

Randomised controlled feasibility trial (n=40) comparing a 21-day meditation-based DIPP versus a music-based DIPP control, each followed by a supervised 25 mg psilocybin session at University College London.

Started
March 1, 2025
Type
interventional
Blinding
single
Randomized
Yes
Registry ID
NCT06815653
RecruitingPhase I

Psilocybin for Methamphetamine Addiction

Open-label, single-arm early Phase I pilot (n=20) assessing feasibility and tolerability of a single 25 mg oral psilocybin dose to promote abstinence in adults receiving residential treatment for methamphetamine dependence.

Started
March 1, 2025
Type
interventional
Blinding
none
Randomized
No
Registry ID
NCT06899594
RecruitingPhase I/II

Psychedelic-assisted Group Program for First Responders

This interventional feasibility study (n=32) will evaluate the impact of oral psilocybin (10mg) combined with a 12-week group-based programme tailored for firefighters.

Started
January 1, 2025
Type
interventional
Blinding
none
Randomized
Yes
Registry ID
NCT06471959
CompletedPhase NA

Low-Income Group Psilocybin Assisted Therapy for Depression (LIGPATD)

Open-label, single-group feasibility study (n=20) evaluating group psilocybin-assisted therapy (two psilocybin sessions) for low-income adults with major depression in Oregon.

Started
August 1, 2024
Type
interventional
Blinding
none
Randomized
No
Registry ID
NCT06372197

Explore further

Search all Psilocybin papers Search all Implementation & Service Delivery trials Full Psilocybin profile Full Implementation & Service Delivery profile